Displaying 13 - 24 of 136
Metabolism, Alcohol & Toxicity

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Approaching MASH as a metabolic disease with the need for holistic therapy

Webcasts
View
Metabolism, Alcohol & Toxicity

Panel Discussion

Webcasts
View
Metabolism, Alcohol & Toxicity

Summary and Closing remarks

Webcasts
View
Metabolism, Alcohol & Toxicity

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Discussion and Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity

Introduction

Webcasts
View
Displaying 13 - 24 of 136